search
Back to results

A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (NOR-CACTUS)

Primary Purpose

Carpal Tunnel Syndrome

Status
Recruiting
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Surgical carpal tunnel release
Injection, Triamcinolone Hexacetonide, Per 5 Mg
Sponsored by
Diakonhjemmet Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carpal Tunnel Syndrome focused on measuring Surgery, Corticosteroid injection, Ultrasound guided intervention, Nerve conduction studies, Randomized controlled trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult (≥18 years of age)
  2. Patient history indicating CTS
  3. Neurophysiological examination performed within 6 months
  4. Diagnosis of CTS based on:

    1. Classic/probable or possible symptoms, and neurophysiological findings consistent with CTS

      Or, in case of normal neurophysiological findings:

    2. Classic/probable symptoms and positive physical exam findings and/or nighttime symptoms
  5. Mild to moderate symptoms (intermittent, interfering with everyday life, and/or disturb sleep)

Exclusion Criteria:

  1. Previous CTS surgery or corticosteroid injection in the carpal tunnel in the relevant hand
  2. Diagnosis of severe CTS, based on history and examination indicating severe CTS with constant symptoms including pain, loss of sensibility, dexterity or reduced temperature sensation, weakness of thumb abduction and opposition, or atrophy of thenar musculature. Disappearance of pain may indicate permanent sensory loss.
  3. History suggesting underlying causes of CTS e.g. inflammatory wrist arthritis and/or flexor tenosynovitis
  4. Previous significant trauma or fracture, deformity or tumor in the wrist or hand in the relevant hand
  5. Presence of conditions affecting a normal nerve function e.g. cervical disc herniation, polyneuropathy or previous nerve injury
  6. Major co-morbidities, such as severe malignancies, severe or uncontrolled infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV) and/or severe respiratory diseases, severe renal failure, active ulcus ventriculi, leukopenia and/or thrombocytopenia
  7. Severe psychiatric or mental disorders
  8. Local infection or wound in the affected hand/wrist
  9. Any other medical condition that according to the treating physician and/or local guidelines makes adherence to treatment protocol impossible
  10. Inadequate birth control1, pregnancy2, and/or breastfeeding (current at screening or planned within the duration of the study)
  11. Known hypersensitivity to Triamcinolone Hexacetonide (Lederspan) or any of the excipients (sorbitol, polysorbate or benzyl alcohol)
  12. Concomitant therapy with CYP3A-inhibitors or digitalis glycosides
  13. Patients vaccinated or immunized with live virus vaccines within 2 weeks of treatment
  14. Alcohol or other substance abuse
  15. Language barriers
  16. Other factors which make adherence to study protocol impossible

Sites / Locations

  • Department of Surgery and Anesthesiology, Diakonhjemmet HospitalRecruiting
  • Department of Rheumatology, Diakonhjemmet Hospital
  • Department of Orthopedic Surgery, Martina Hansens HospitalRecruiting
  • Department of Rheumatology, Martina Hansens HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Surgery treatment strategy

Injection treatment strategy

Arm Description

Primary open surgical carpal tunnel release. Treatment effect is monitored on scheduled follow-up visits. Re-operation may be performed if medically indicated (e.g. postoperative complication, or failure of the primary procedure)

Primary treatment with ultrasound-guided corticosteroid injection. Treatment effect is monitored on scheduled follow-up visits. One additional injection may be administered, and subsequently surgical carpal tunnel release is performed in case of unsatisfactory treatment effect of the injection therapy. Treatment effect is graded on a 5-leve scale by subject from 1 (complete improvement) to 5 (severe worsening) of symptoms. Incomplete improvement (score 2 or higher) results in a second injection or secondary surgery.

Outcomes

Primary Outcome Measures

Successful treatment result after 12 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 12 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The primary outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 12 months after start of the study intervention.

Secondary Outcome Measures

Successful treatment result after 3 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 3 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 3 months after start of the study intervention.
Successful treatment result after 6 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 6 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 6 months after start of the study intervention.
Successful treatment result after 24 months
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 24 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 24 months after start of the study intervention.
Boston Carpal Tunnel Questionnaire Symptom Severity Scale
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (range 1-5) Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5, used as outcome measure.
Boston Carpal Tunnel Questionnaire Functional Status Scale
Boston Carpal Tunnel Questionnaire Functional Status Scale (range 1-5) Boston Carpal Tunnel Questionnaire Functional Status Scale (BCTQ FSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related functional impairment. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5, used as outcome measure.
Nerve conduction studies: Motor median nerve distal latency
Nerve conduction studies of motor median nerve distal latency (milliseconds) Measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Nerve conduction studies: Motor median nerve proximal latency
Nerve conduction studies of motor median nerve proximal latency (milliseconds) Median nerve measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Nerve conduction studies: Motor median nerve amplitude
Nerve conduction studies of motor median nerve amplitude (millivolts) Median nerve measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Nerve conduction studies: Motor median nerve conduction velocity
Nerve conduction studies of motor median nerve amplitude conduction velocity (meters per second) Median nerve measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Nerve conduction studies: Motor ulnar nerve distal latency
Nerve conduction studies of motor ulnar nerve distal latency (milliseconds) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Motor ulnar nerve proximal latency
Nerve conduction studies of motor ulnar nerve proximal latency (milliseconds) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Motor ulnar nerve amplitude
Nerve conduction studies of motor ulnar nerve amplitude (millivolts) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Motor ulnar nerve conduction velocity
Nerve conduction studies of motor ulnar nerve conduction velocity (meters per second) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Nerve conduction studies: Sensory median nerve latency
Nerve conduction studies of sensory median nerve latency (milliseconds) Median nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory median nerve amplitude
Nerve conduction studies of sensory median nerve amplitude (microvolts) Median nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory median nerve conduction velocity
Nerve conduction studies of sensory median nerve conduction velocity (meters per second) Median nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory ulnar nerve latency
Nerve conduction studies of sensory ulnar nerve latency (milliseconds) Ulnar nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory ulnar nerve amplitude
Nerve conduction studies of sensory ulnar nerve amplitude (microvolts) Ulnar nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Nerve conduction studies: Sensory ulnar nerve conduction velocity
Nerve conduction studies of sensory ulnar nerve conduction velocity (meters per second) Ulnar nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Electromyography: Spontaneous activity
Electromyography recording spontaneous activity in m.abductor pollicis brevis (Yes/No)
Electromyography: Chronic neurogenic changes
Electromyography recording chronic neurogenic changes in m.abductor pollicis brevis (Yes/No)
Nerve conduction studies: Bland score
Scoring of motor and sensory nerve conduction studies using the Bland scoring system (Bland, et al. 2000): 0: normal 1: very mild 2: mild 3: moderate 4: severe 5: very severe 6: extremely severe 7: not gradable
Semmes-Weinstein monofilament test
Bilateral test of sensory function in digits 1,2 and 5 using a 2.83 monofilament. Graded absent/present.
Grip strength
Test of grip strength using dynamometer. Range 0-90 kg.
Grip ability test (GAT)
Simplified version of the Sollerman grip function test. Measures time for subject to perform 3 tasks: Pulling a tubular bandage over the hand, putting a paper clip on an envelope, and pouring water from a jar into a cup. Range 0-60 seconds for each task. Outcome measure is calculated as: tubular bandage (seconds) x 1.8 + paper clip on an envelope (seconds) + pouring water (seconds) x 1.8
Patient assessment of treatment effect on symptoms
Patient-reported assessment of treatment effect on symptoms (current state compared to before treatment), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of expected treatment effect on symptoms
Patient-reported expectation (reported by the patient prior to treatment) of the treatment's effect on symptoms, reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of CTS symptoms
Patient-reported assessment of CTS-related symptoms (current state), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of CTS-related functional impairment
Patient-reported assessment of current CTS-related functional impairment (current state), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Patient assessment of acceptability of CTS-related symptoms and functional disability
Patient assessment if the current CTS-related symptoms and functional disability are acceptable (yes or no)
Ultrasound measure of proximal cross-sectional area of the median nerve
Bilateral evaluation of the proximal cross-sectional area of the median nerve (square millimeters) (as specified in protocol)
Ultrasound measure of distal cross-sectional area of the median nerve
Bilateral evaluation of the distal cross-sectional area of the median nerve (square millimeters) (as specified in protocol)
Ultrasound measures of vascularity of the median nerve in the carpal tunnel
Bilateral evaluation of vascularity of the median nerve in the carpal tunnel. Scored 0 to 3 0: no PD signal 1: 1 singular blood vessel 2: 2-3 single blood vessels or 2 confluent 3: ≥4 single blood vessels or ≥ 3 confluent
Disabilities of the Arm, Shoulder, and Hand (Quick-DASH)
11-item patient reported outcome measure for disabilities of the arm, shoulder, and hand. (Beaton DE, et al. 2005)
Patient pain assessment
Patient-reported CTS-related pain on a 0-100 mm visual analogue scale (VAS), where 0 indicates no pain and 100 indicates worst possible pain.
Work Productivity and Activity Impairment Questionnaire (WPAI)
Patient-reported outcome of physical function in work and activity. (Reilly MC, et al. 1993)
Days of work absence since start of intervention
Number of days of work absence due to CTS or treatment of CTS since start of intervention
EuroQoL 5-dimension health-related quality of life (EQ5D-5L)
EuroQoL 5-dimension patient-reported outcome for health-related quality of life. (Herdman M, et al. 2011)
Adverse events
Number and nature of adverse events and serious adverse events
Successful treatment after 1 corticosteroid injection
Only applicable in the injection treatment strategy arm. Subjects who have received 1 corticosteroid injection who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5) without surgery
Successful treatment after 2 corticosteroid injections
Only applicable in the injection treatment strategy arm. Subjects who have received 2 corticosteroid injections who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5) without surgery
Successful treatment after secondary surgery
Only applicable in the injection treatment strategy arm. Subjects who have received 1 or 2 corticosteroid injections and secondary surgery who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5)
Undergone re-operation
Subject have received a re-operation (yes/no) A participant who for any reason requires a re-operation, either after primary surgery (surgery arm) or after corticosteroid injection therapy and delayed surgery (injection arm). Reasons for re-operation may, for instance, be wound complications or failure of the initial procedure. NOTE: Secondary (delayed) surgery in a participant in the injection arm in accordance with the study treatment algorithm is not considered a re-operation.
Cost of treatment
Direct treatment-associated costs, including hospital visits and procedures/interventions. Based on the diagnosis-related group (DRG) pricing system and codified price-lists for medical procedures.

Full Information

First Posted
March 14, 2022
Last Updated
October 18, 2023
Sponsor
Diakonhjemmet Hospital
Collaborators
Oslo University Hospital, Martina Hansen's Hospital, South-Eastern Norway Regional Health Authority
search

1. Study Identification

Unique Protocol Identification Number
NCT05306548
Brief Title
A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome
Acronym
NOR-CACTUS
Official Title
The NOR-CACTUS Trial - A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 8, 2022 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diakonhjemmet Hospital
Collaborators
Oslo University Hospital, Martina Hansen's Hospital, South-Eastern Norway Regional Health Authority

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Carpal tunnel syndrome (CTS) causes numbness and pain in the hand and arm, and is an important cause of work absence and disability. The aim of the NOR-CACTUS Trial is to compare outcomes of a treatment strategy where the initial treatment is up to two ultrasound-guided corticosteroid injections, followed by scheduled clinical assessment of treatment effect, and subsequent surgery if needed, to a treatment strategy where surgery is the first-line treatment. Participants will be randomized to one of the treatment strategies, and followed up for two years after start of the study intervention. Outcomes will include patient-reported, clinical, functional and neurophysiological measures, and health-economic aspects. The hypothesis of the study is that there is no difference between the two treatment groups in the percentage of patients with a satisfactory symptom relief (treatment success) one year after the initial therapeutic intervention.
Detailed Description
CTS is the most common non-traumatic hand disorder, prevalent in approximately 4% of the adult population. The condition may have a substantial impact on an individual's quality of life, ability to accomplish activities of daily living, and to perform occupational duties. Associated healthcare costs represent a significant socioeconomic burden. Currently, many patients with mild and moderate CTS treated surgically without a preceding trial of less invasive non-surgical therapies. An increase in the use of non-surgical first-line therapies (e.g. corticosteroid injection into the carpal tunnel), while reserving surgery for refractory cases, aim to optimize the trade-off between treatment risk and benefit, while also ensuring appropriate use of health resources. However, there is a lack of studies directly comparing the efficacy of corticosteroid injections to surgery, and the long-term safety of corticosteroid injections has not been investigated. It is not well-known if patients who are initially treated with corticosteroid injections will eventually need to proceed to surgery, and therefore may have to endure the symptoms for a longer period of time, with potentially worse long-term outcomes, compared to patients who has surgery as first-line treatment. On the other hand, it is not beneficial if patients are unnecessarily exposed to the risks associated with surgery, if symptoms could have been satisfactory resolved with a non-surgical method. The current study will assess if first-line treatment with up to two ultrasound-guided corticosteroid injections is non-inferior to surgery with regards to treatment success. A less invasive treatment approach might result in important benefits to the patient, e.g. less pain, reduced risk of complications, and faster return to work and activities. This might also be of importance to family members, as many CTS patients are at an age where they have care responsibilities. Non-surgical treatments might benefit society by decreasing work absence and reducing health expenditure, and allowing better access to surgical services for other patient groups. High quality documentation is needed to provide a base for future treatment guidelines. Evidence based clinical guidelines provide treatment decision support and help reduce national and regional differences in treatment practices, and ensure that all patients have equal access to evidence-based treatment. In the NOR-CACTUS trial, adult individuals with idiopathic CTS of a mild-to-moderate degree will be randomized to receive either A) Primary open surgical carpal tunnel release, or B) Up to two ultrasound-guided corticosteroid (triamcinolone hexacetonide) injections in the carpal tunnel, and subsequent open surgical carpal tunnel release in case of unsatisfactory treatment result. Participants will be randomized to receive one of the treatment strategies, and followed for two years, with the primary endpoint being successful treatment result one year after start of the intervention. The hypothesis of the study is that the percentage of patients with a satisfactory symptom relief (treatment success) one year after the initial therapeutic intervention in the injection treatment strategy arm is non-inferior to that of the surgery treatment arm. The primary outcome is based on the disease-specific patient-reported outcome Boston Carpal Tunnel Questionnaire (BCTQ) symptom severity scale (SSS). Further outcomes will include other patient-reported, clinical, functional and neurophysiological measures, and health-economic aspects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carpal Tunnel Syndrome
Keywords
Surgery, Corticosteroid injection, Ultrasound guided intervention, Nerve conduction studies, Randomized controlled trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Two-arm, prospective, multi-center, parallel-group, open-label assessor-blinded non-inferiority treatment strategy study
Masking
Outcomes Assessor
Masking Description
Participants in both strategy arms will have the site for injection/surgery covered with a adhesive bandage prior to assessment by blinded outcome assessors.
Allocation
Randomized
Enrollment
258 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Surgery treatment strategy
Arm Type
Active Comparator
Arm Description
Primary open surgical carpal tunnel release. Treatment effect is monitored on scheduled follow-up visits. Re-operation may be performed if medically indicated (e.g. postoperative complication, or failure of the primary procedure)
Arm Title
Injection treatment strategy
Arm Type
Experimental
Arm Description
Primary treatment with ultrasound-guided corticosteroid injection. Treatment effect is monitored on scheduled follow-up visits. One additional injection may be administered, and subsequently surgical carpal tunnel release is performed in case of unsatisfactory treatment effect of the injection therapy. Treatment effect is graded on a 5-leve scale by subject from 1 (complete improvement) to 5 (severe worsening) of symptoms. Incomplete improvement (score 2 or higher) results in a second injection or secondary surgery.
Intervention Type
Procedure
Intervention Name(s)
Surgical carpal tunnel release
Other Intervention Name(s)
Open surgical carpal tunnel release
Intervention Description
Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
Intervention Type
Drug
Intervention Name(s)
Injection, Triamcinolone Hexacetonide, Per 5 Mg
Other Intervention Name(s)
Ultrasound-guided corticosteroid injection
Intervention Description
Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
Primary Outcome Measure Information:
Title
Successful treatment result after 12 months
Description
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 12 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The primary outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 12 months after start of the study intervention.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Successful treatment result after 3 months
Description
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 3 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 3 months after start of the study intervention.
Time Frame
3 months
Title
Successful treatment result after 6 months
Description
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 6 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 6 months after start of the study intervention.
Time Frame
6 months
Title
Successful treatment result after 24 months
Description
Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5 after 24 months Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5. The outcome measure is achievement of BCTQ SSS ≤ 1.5, interpreted as a successful treatment result, 24 months after start of the study intervention.
Time Frame
24 months
Title
Boston Carpal Tunnel Questionnaire Symptom Severity Scale
Description
Boston Carpal Tunnel Questionnaire Symptom Severity Scale (range 1-5) Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ SSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related symptom severity. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5, used as outcome measure.
Time Frame
0-24 months
Title
Boston Carpal Tunnel Questionnaire Functional Status Scale
Description
Boston Carpal Tunnel Questionnaire Functional Status Scale (range 1-5) Boston Carpal Tunnel Questionnaire Functional Status Scale (BCTQ FSS, Levine et. al 1993) is a disease-specific patient-reported outcome for CTS-related functional impairment. 11 items are scored by the patient on an ordinal scale from 1 (best) to 5 (worst), providing a mean score ranged 1-5, used as outcome measure.
Time Frame
0-24 months
Title
Nerve conduction studies: Motor median nerve distal latency
Description
Nerve conduction studies of motor median nerve distal latency (milliseconds) Measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor median nerve proximal latency
Description
Nerve conduction studies of motor median nerve proximal latency (milliseconds) Median nerve measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor median nerve amplitude
Description
Nerve conduction studies of motor median nerve amplitude (millivolts) Median nerve measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor median nerve conduction velocity
Description
Nerve conduction studies of motor median nerve amplitude conduction velocity (meters per second) Median nerve measurement points: Distal: at the wrist, 8 cm proximal to the m. abductor pollicis brevis. Proximal: at the cubital fossa
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor ulnar nerve distal latency
Description
Nerve conduction studies of motor ulnar nerve distal latency (milliseconds) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor ulnar nerve proximal latency
Description
Nerve conduction studies of motor ulnar nerve proximal latency (milliseconds) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor ulnar nerve amplitude
Description
Nerve conduction studies of motor ulnar nerve amplitude (millivolts) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Time Frame
0 and 12 months
Title
Nerve conduction studies: Motor ulnar nerve conduction velocity
Description
Nerve conduction studies of motor ulnar nerve conduction velocity (meters per second) Ulnar nerve measurement points: Distal: at the wrist, 8 cm proximal to the abductor digiti minimi Proximal: 3 cm distal to the medial epicondyle of the elbow
Time Frame
0 and 12 months
Title
Nerve conduction studies: Sensory median nerve latency
Description
Nerve conduction studies of sensory median nerve latency (milliseconds) Median nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Time Frame
0 and 12 months
Title
Nerve conduction studies: Sensory median nerve amplitude
Description
Nerve conduction studies of sensory median nerve amplitude (microvolts) Median nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Time Frame
0 and 12 months
Title
Nerve conduction studies: Sensory median nerve conduction velocity
Description
Nerve conduction studies of sensory median nerve conduction velocity (meters per second) Median nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Time Frame
0 and 12 months
Title
Nerve conduction studies: Sensory ulnar nerve latency
Description
Nerve conduction studies of sensory ulnar nerve latency (milliseconds) Ulnar nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Time Frame
0 and 12 months
Title
Nerve conduction studies: Sensory ulnar nerve amplitude
Description
Nerve conduction studies of sensory ulnar nerve amplitude (microvolts) Ulnar nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Time Frame
0 and 12 months
Title
Nerve conduction studies: Sensory ulnar nerve conduction velocity
Description
Nerve conduction studies of sensory ulnar nerve conduction velocity (meters per second) Ulnar nerve measurement points: Palmar branch, 8 cm distance, 4th digit with 14 cm distance
Time Frame
0 and 12 months
Title
Electromyography: Spontaneous activity
Description
Electromyography recording spontaneous activity in m.abductor pollicis brevis (Yes/No)
Time Frame
0 and 12 months
Title
Electromyography: Chronic neurogenic changes
Description
Electromyography recording chronic neurogenic changes in m.abductor pollicis brevis (Yes/No)
Time Frame
0 and 12 months
Title
Nerve conduction studies: Bland score
Description
Scoring of motor and sensory nerve conduction studies using the Bland scoring system (Bland, et al. 2000): 0: normal 1: very mild 2: mild 3: moderate 4: severe 5: very severe 6: extremely severe 7: not gradable
Time Frame
0 and 12 months
Title
Semmes-Weinstein monofilament test
Description
Bilateral test of sensory function in digits 1,2 and 5 using a 2.83 monofilament. Graded absent/present.
Time Frame
0-24 months
Title
Grip strength
Description
Test of grip strength using dynamometer. Range 0-90 kg.
Time Frame
0-24 months
Title
Grip ability test (GAT)
Description
Simplified version of the Sollerman grip function test. Measures time for subject to perform 3 tasks: Pulling a tubular bandage over the hand, putting a paper clip on an envelope, and pouring water from a jar into a cup. Range 0-60 seconds for each task. Outcome measure is calculated as: tubular bandage (seconds) x 1.8 + paper clip on an envelope (seconds) + pouring water (seconds) x 1.8
Time Frame
0-24 months
Title
Patient assessment of treatment effect on symptoms
Description
Patient-reported assessment of treatment effect on symptoms (current state compared to before treatment), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Time Frame
3-24 months
Title
Patient assessment of expected treatment effect on symptoms
Description
Patient-reported expectation (reported by the patient prior to treatment) of the treatment's effect on symptoms, reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Time Frame
0 months
Title
Patient assessment of CTS symptoms
Description
Patient-reported assessment of CTS-related symptoms (current state), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Time Frame
0-24 months
Title
Patient assessment of CTS-related functional impairment
Description
Patient-reported assessment of current CTS-related functional impairment (current state), reported on a 5-level ordinal (Likert) scale from 1 (best) to 5 (worst).
Time Frame
0-24 months
Title
Patient assessment of acceptability of CTS-related symptoms and functional disability
Description
Patient assessment if the current CTS-related symptoms and functional disability are acceptable (yes or no)
Time Frame
0-24 months
Title
Ultrasound measure of proximal cross-sectional area of the median nerve
Description
Bilateral evaluation of the proximal cross-sectional area of the median nerve (square millimeters) (as specified in protocol)
Time Frame
0-24 months
Title
Ultrasound measure of distal cross-sectional area of the median nerve
Description
Bilateral evaluation of the distal cross-sectional area of the median nerve (square millimeters) (as specified in protocol)
Time Frame
0-24 months
Title
Ultrasound measures of vascularity of the median nerve in the carpal tunnel
Description
Bilateral evaluation of vascularity of the median nerve in the carpal tunnel. Scored 0 to 3 0: no PD signal 1: 1 singular blood vessel 2: 2-3 single blood vessels or 2 confluent 3: ≥4 single blood vessels or ≥ 3 confluent
Time Frame
0-24 months
Title
Disabilities of the Arm, Shoulder, and Hand (Quick-DASH)
Description
11-item patient reported outcome measure for disabilities of the arm, shoulder, and hand. (Beaton DE, et al. 2005)
Time Frame
0-24 months
Title
Patient pain assessment
Description
Patient-reported CTS-related pain on a 0-100 mm visual analogue scale (VAS), where 0 indicates no pain and 100 indicates worst possible pain.
Time Frame
0-24 months
Title
Work Productivity and Activity Impairment Questionnaire (WPAI)
Description
Patient-reported outcome of physical function in work and activity. (Reilly MC, et al. 1993)
Time Frame
0-24 months
Title
Days of work absence since start of intervention
Description
Number of days of work absence due to CTS or treatment of CTS since start of intervention
Time Frame
3-24 months
Title
EuroQoL 5-dimension health-related quality of life (EQ5D-5L)
Description
EuroQoL 5-dimension patient-reported outcome for health-related quality of life. (Herdman M, et al. 2011)
Time Frame
0-24 months
Title
Adverse events
Description
Number and nature of adverse events and serious adverse events
Time Frame
0-24 months
Title
Successful treatment after 1 corticosteroid injection
Description
Only applicable in the injection treatment strategy arm. Subjects who have received 1 corticosteroid injection who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5) without surgery
Time Frame
3-24 months
Title
Successful treatment after 2 corticosteroid injections
Description
Only applicable in the injection treatment strategy arm. Subjects who have received 2 corticosteroid injections who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5) without surgery
Time Frame
3-24 months
Title
Successful treatment after secondary surgery
Description
Only applicable in the injection treatment strategy arm. Subjects who have received 1 or 2 corticosteroid injections and secondary surgery who have attained a successful treatment result (Boston Carpal Tunnel Questionnaire Symptom Severity Scale ≤ 1.5)
Time Frame
3-24 months
Title
Undergone re-operation
Description
Subject have received a re-operation (yes/no) A participant who for any reason requires a re-operation, either after primary surgery (surgery arm) or after corticosteroid injection therapy and delayed surgery (injection arm). Reasons for re-operation may, for instance, be wound complications or failure of the initial procedure. NOTE: Secondary (delayed) surgery in a participant in the injection arm in accordance with the study treatment algorithm is not considered a re-operation.
Time Frame
3-24 months
Title
Cost of treatment
Description
Direct treatment-associated costs, including hospital visits and procedures/interventions. Based on the diagnosis-related group (DRG) pricing system and codified price-lists for medical procedures.
Time Frame
0-24 months
Other Pre-specified Outcome Measures:
Title
Use of hospital services
Description
Use of hospital services from The Norwegian Patient Register (NPR)
Time Frame
0-24 months
Title
Use of primary care resources
Description
Use of primary care resources based on data from Norwegian municipal patient- and user register (KPR)
Time Frame
0-24 months
Title
Work participation
Description
Work participation based on data from Statistics Norways's (SSB) event database for social services (FD Trygd)
Time Frame
0-24 months
Title
Total cost
Description
Unit costs will be assigned to each type of service by means of the diagnosis-related group (DRG) pricing system, and the price list of the Norwegian Medicines Agency. For each patient total costs will be estimated utilization of health care and social services. The mean symptom severity and cost in the two treatment arms will be used to estimate a cost-effectiveness ratio for the treatment strategies.
Time Frame
0-24 months
Title
Environmental impact analysis
Description
Greenhouse gas emissions expressed as CO2 equivalents
Time Frame
0-24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (≥18 years of age) Patient history indicating CTS Neurophysiological examination performed within 6 months Diagnosis of CTS based on: Classic/probable or possible symptoms, and neurophysiological findings consistent with CTS Or, in case of normal neurophysiological findings: Classic/probable symptoms and positive physical exam findings and/or nighttime symptoms Mild to moderate symptoms (intermittent, interfering with everyday life, and/or disturb sleep) Exclusion Criteria: Previous CTS surgery or corticosteroid injection in the carpal tunnel in the relevant hand Diagnosis of severe CTS, based on history and examination indicating severe CTS with constant symptoms including pain, loss of sensibility, dexterity or reduced temperature sensation, weakness of thumb abduction and opposition, or atrophy of thenar musculature. Disappearance of pain may indicate permanent sensory loss. History suggesting underlying causes of CTS e.g. inflammatory wrist arthritis and/or flexor tenosynovitis Previous significant trauma or fracture, deformity or tumor in the wrist or hand in the relevant hand Presence of conditions affecting a normal nerve function e.g. cervical disc herniation, polyneuropathy or previous nerve injury Major co-morbidities, such as severe malignancies, severe or uncontrolled infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV) and/or severe respiratory diseases, severe renal failure, active ulcus ventriculi, leukopenia and/or thrombocytopenia Severe psychiatric or mental disorders Local infection or wound in the affected hand/wrist Any other medical condition that according to the treating physician and/or local guidelines makes adherence to treatment protocol impossible Inadequate birth control1, pregnancy2, and/or breastfeeding (current at screening or planned within the duration of the study) Known hypersensitivity to Triamcinolone Hexacetonide (Lederspan) or any of the excipients (sorbitol, polysorbate or benzyl alcohol) Concomitant therapy with CYP3A-inhibitors or digitalis glycosides Patients vaccinated or immunized with live virus vaccines within 2 weeks of treatment Alcohol or other substance abuse Language barriers Other factors which make adherence to study protocol impossible
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ulf G Sundin, MD, PhD
Phone
+4740614198
Email
uffe.sundin@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Siri Lillegraven, MD, MPH, PhD
Email
siri.lillegraven@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hilde B Hammer, MD, PhD
Organizational Affiliation
Diakonhjemmet Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Surgery and Anesthesiology, Diakonhjemmet Hospital
City
Oslo
State/Province
Norge
ZIP/Postal Code
1450
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulf G Sundin, MD, PhD
Phone
+4740614198
Email
uffe.sundin@gmail.com
Facility Name
Department of Rheumatology, Diakonhjemmet Hospital
City
Oslo
ZIP/Postal Code
0319
Country
Norway
Individual Site Status
Active, not recruiting
Facility Name
Department of Orthopedic Surgery, Martina Hansens Hospital
City
Sandvika
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Geir Hjorthaug, MD, PhD
Email
geir.Aasmund.Hjorthaug@mhh.no
Facility Name
Department of Rheumatology, Martina Hansens Hospital
City
Sandvika
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louise Clark, MD
Email
louise.Erika.Clark@mhh.no

12. IPD Sharing Statement

Citations:
PubMed Identifier
10918269
Citation
Bland JD. A neurophysiological grading scale for carpal tunnel syndrome. Muscle Nerve. 2000 Aug;23(8):1280-3. doi: 10.1002/1097-4598(200008)23:83.0.co;2-y.
Results Reference
background
PubMed Identifier
8245050
Citation
Levine DW, Simmons BP, Koris MJ, Daltroy LH, Hohl GG, Fossel AH, Katz JN. A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. J Bone Joint Surg Am. 1993 Nov;75(11):1585-92. doi: 10.2106/00004623-199311000-00002.
Results Reference
background
PubMed Identifier
15866967
Citation
Beaton DE, Wright JG, Katz JN; Upper Extremity Collaborative Group. Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am. 2005 May;87(5):1038-46. doi: 10.2106/JBJS.D.02060.
Results Reference
background
PubMed Identifier
10146874
Citation
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353-65. doi: 10.2165/00019053-199304050-00006.
Results Reference
background
PubMed Identifier
21479777
Citation
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9.
Results Reference
background

Learn more about this trial

A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome

We'll reach out to this number within 24 hrs